Why the study?
Visit-to-visit SBP variability is a CVD risk factor in T2DM, but whether this differs by presence or absence of previous CVD was unclear.
Does visit-to-visit systolic blood pressure variability correlate with estimated cardiovascular risk in patients with type 2 diabetes with and without previous cardiovascular disease?
Does visit-to-visit systolic blood pressure variability correlate with estimated cardiovascular risk in patients with type 2 diabetes with and without previous cardiovascular disease?
Visit-to-visit systolic blood pressure variability is higher in T2DM patients with established CVD and is independently associated with higher estimated cardiovascular risk across the CVD continuum.
May refine CVD risk stratification in T2DM; hypothesis-generating for variability-targeted interventions.
OBJECTIVE: Visit-to-visit variability in SBP is a risk factor for cardiovascular disease (CVD) in type 2 diabetes (T2DM) but little is known on whether in T2DM this differs according to presence or absence of previous CVD. METHODS: We retrospectively assessed the coefficient of variation (standard deviation/mean) of mean SBP (SBP-CV) in 970 patients (44% with established CVD) attending at least four times our secondary care diabetes clinic in 2015-2016 to estimate their risk of CVD-related events using the 10-year UKPDS Risk Engine. RESULTS: Patients with established CVD had a higher SBP-CV (10.3 ± 4.8%) than patients without CVD (8.9 ± 4.3%; P < 0.001) as confirmed by the progressively higher prevalence of established CVD in tertiles of SBP-CV (36.6, 46.1, and 52.0%; P < 0.001), in association with more aggressive and complex drug regimens. On the basis of the 10-year UKPDS Risk Engine, higher SBP-CV values were associated with increased risks of the CVD outcomes regardless of the previous history of CVD in multivariate models. CONCLUSION: Visit-to-visit variability of SBP was greater in T2DM patients with that in those without previous history of CVD, and maintained an independent association with higher estimated risk of CVD-related events regardless of the history of CVD, suggesting that its prognostic significance is relevant in the entire CVD continuum of patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Radaelli et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: